Rhumbline Advisers Boosts Stock Holdings in Fractyl Health, Inc. (NASDAQ:GUTS)

Rhumbline Advisers boosted its stake in shares of Fractyl Health, Inc. (NASDAQ:GUTS) by 73.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,626 shares of the company’s stock after purchasing an additional 10,826 shares during the period. Rhumbline Advisers owned approximately 0.05% of Fractyl Health worth $53,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Stoneridge Investment Partners LLC acquired a new position in shares of Fractyl Health during the 4th quarter valued at $45,000. JPMorgan Chase & Co. lifted its holdings in shares of Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after acquiring an additional 11,406 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Fractyl Health during the 3rd quarter valued at $85,000. Barclays PLC lifted its holdings in shares of Fractyl Health by 1,754.7% during the 3rd quarter. Barclays PLC now owns 47,796 shares of the company’s stock valued at $121,000 after acquiring an additional 45,219 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Fractyl Health by 166.5% during the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock valued at $1,269,000 after acquiring an additional 313,335 shares in the last quarter.

Analysts Set New Price Targets

Separately, Morgan Stanley reduced their target price on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd.

Insider Buying and Selling

In related news, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the sale, the insider now owns 153,544 shares of the company’s stock, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Harith Rajagopalan sold 90,972 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.82, for a total transaction of $165,569.04. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $894,218.78. The trade was a 15.62 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $1.35 on Wednesday. Fractyl Health, Inc. has a twelve month low of $1.27 and a twelve month high of $9.04. The firm has a market capitalization of $66.04 million and a price-to-earnings ratio of -0.11. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The firm’s fifty day simple moving average is $1.71 and its 200 day simple moving average is $2.23.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.08). As a group, equities research analysts expect that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.